Spero Therapeutics (NASDAQ:SPRO) Stock Rating Lowered by Wall Street Zen

Spero Therapeutics (NASDAQ:SPRO) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

Other analysts have also recently issued reports about the company. Zacks Research cut Spero Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, October 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Spero Therapeutics in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $5.00.

Spero Therapeutics Stock Up 0.9%

Shares of NASDAQ:SPRO opened at $2.35 on Friday. Spero Therapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $3.22. The firm’s 50-day simple moving average is $2.35 and its 200-day simple moving average is $2.30. The company has a market cap of $132.40 million, a price-to-earnings ratio of -2.97 and a beta of 1.46.

Spero Therapeutics (NASDAQ:SPRO) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.12. Spero Therapeutics had a negative net margin of 108.11% and a negative return on equity of 125.91%. The firm had revenue of $5.44 million during the quarter, compared to the consensus estimate of $12.00 million. On average, research analysts forecast that Spero Therapeutics will post -1.2 EPS for the current year.

Insider Activity at Spero Therapeutics

In related news, insider Esther Rajavelu sold 40,270 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $2.37, for a total value of $95,439.90. Following the sale, the insider owned 869,450 shares in the company, valued at $2,060,596.50. This represents a 4.43% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 5.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Spero Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Capital Asset Advisory Services LLC purchased a new stake in Spero Therapeutics during the second quarter worth $94,000. Axxcess Wealth Management LLC acquired a new position in shares of Spero Therapeutics during the 2nd quarter worth $94,000. XTX Topco Ltd purchased a new stake in shares of Spero Therapeutics in the 2nd quarter worth about $100,000. Quadrature Capital Ltd purchased a new stake in shares of Spero Therapeutics in the 2nd quarter worth about $90,000. Finally, Invesco Ltd. acquired a new stake in Spero Therapeutics in the 2nd quarter valued at about $43,000. 25.60% of the stock is owned by institutional investors and hedge funds.

About Spero Therapeutics

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.